FFR in non-ST elevation myocardial infarction

Original Title: Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-St segment elevation myocardial infarction: the British Heart Foundation FAMOUS–NSTEMI randomized trial. Reference: Jamie Layland et al. European Heart Journal (2015) 36, 100–111

Courtesy of Dr. José Amadeo Guillermo Álvarez.

Several studies have established the value of fractional flow reserve (FFR) in guiding PCI for patients with stable coronary disease. However, this has not clearly been established for patients with ACS, where the main concerns are that the possible alteration of the microvascular bed may not allow maximum vasodilation required to measure, or that plate instability may cause events, regardless the level of obstruction.

The FAMOUS-NSTEMI study randomized 350 NSTEMI patients and at least one stenosis ≥ 30% to angiography guided vs. FFR guided management. The angiographic study was done at a mean time of three days after ischemia and, even though FFR was measured in all patients, it was informed only in one of the groups.

Results
At one year follow up, primary end point defined as the number of patients that had initially received medical treatment alone, was significantly higher in the FFR group [40 (22.7%) vs. 23 (13.2%, difference 9.5% (95% CI: 1.4%, 17.7%), P . 0.022]. This difference persisted after 12 months follow up [79.0 vs. 86.8%, difference 7.8% (20.2%, 15.8%), p= 0.054.

As regards clinical events, there was a tendency towards more MI associated to revascularization (PCI or CABG) in the angiography guided group (6.3% vs 2.8% p=0.12) and more major cardiac events, excluding peri-intervention infarction, in the FFR group (5.7% vs 2.9% p=0.25)

Commentary 
In NSTEMI acute coronary syndromes, although there are concerns regarding the influence of plate instability related events over the possibility to achieve maximum hyperemia, some studies suggest that measuring fractional flow reserve could be a valid alternative for both intermediate culprit lesion assessment, and as a complete revascularization strategy for patients with multivessel disease. In the FAME study, the third part of the included population had unstable angina or non-STEMI and, even though their two year evolution saw more events than the stable angina population, the difference in favor of FFR was similar. In the FAMOUS-NSTEMI, the angiography + FFR guided group, where the study was done at a mean time of 3 days after the most recent episode of pain, after 12 months, more patients received medical treatment alone with similar incidence of adverse major cardiac events; however, given the low events rate and the small number of patients, the trial has no statistical power to detect differences in the latter, which is why we should not make conclusions on this regard. Further research is required to define the role of FFR in unstable patients.

Courtesy of Dr. José Amadeo Guillermo Álvarez.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...